Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27666619 | 0.86 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL29739381 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL20186996 | 0.81 | KDM4E (0.43) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL1438722 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL11132382 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL20187007 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL20186988 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL8851985 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL1344362 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL15325676 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1HPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| CN-112038496-B | Iridium complex, light-emitting element, display device, electronic device, and lighting device | 株式会社半导体能源研究所 | 2025-02-25 | — | — | CN | disclosed |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| US-12225748-B2 | Light-emitting element, display device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| US-20240397738-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-11-28 | — | — | US | disclosed |
| US-20240292646-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | US | disclosed |
| US-20030186990-A1 | Prodrugs of hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030114472-A1 | Viricides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| EP-1002795-B1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1270560-A1 | Hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1225874-A1 | ANTIVIRAL COMPOSITIONS | Janssen Pharmaceutica N.V. (BE) | 2002-07-31 | — | — | EP | disclosed |
| CN-1322198-A | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2001-11-14 | — | — | CN | disclosed |
| WO-2001022938-A1 | ANTIVIRAL COMPOSITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-05 | — | — | WO | disclosed |
| EP-1002795-A1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000027825-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240397738-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | EHD1, ESR1, EPHX1 | KDM4E 2159/4885ALDH1A1 1715/4885HPGD 901/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KDM4E 3666/4885ALDH1A1 1142/4885HPGD 3881/4885 |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | KDM4E 813/4885ALDH1A1 3007/4885HPGD 542/4885 |
| US-20030114472-A1 | Viricides | ZC3HAV1, ZC3HAV1L, POLR2H | KDM4E 2154/4885ALDH1A1 2470/4885HPGD 2595/4885 |
| US-12225748-B2 | Light-emitting element, display device, electronic device, and lighting device | EHD1, ESR1, EPHX1 | KDM4E 2159/4885ALDH1A1 1715/4885HPGD 901/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | KDM4E 2050/4885ALDH1A1 4276/4885HPGD 3670/4885 |
| US-20030186990-A1 | Prodrugs of hiv replication inhibiting pyrimidines | CYP2S1, REV1, CYP1B1 | KDM4E 2393/4885ALDH1A1 428/4885HPGD 252/4885 |
| US-20240292646-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | EHD1, ESR1, EPHX1 | KDM4E 2159/4885ALDH1A1 1715/4885HPGD 901/4885 |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | CPN1, CTRL, HPN | KDM4E 2314/4885ALDH1A1 3437/4885HPGD 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.